 The European study, LINES 2009 Low and Intermediate Risk Neuroblastoma European Study, groups together in a single protocol the treatment of all patients with non high risk neuroblastoma NB, with stratification into two groups: low risk and intermediate risk. These two separate cohorts are included in one single protocol to enable patient data from these two groups to be entered into a common database, as the current prognostic classifications determining treatment may evolve further with subsequent more detailed molecular analysis of the tumours. 